Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Decreases By 9.1%

Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,990,000 shares, a decrease of 9.1% from the February 13th total of 2,190,000 shares. Based on an average daily volume of 381,800 shares, the days-to-cover ratio is presently 5.2 days. Approximately 3.6% of the shares of the stock are short sold.

Aldeyra Therapeutics Stock Up 12.0 %

Shares of NASDAQ ALDX opened at $7.86 on Wednesday. Aldeyra Therapeutics has a 12-month low of $2.36 and a 12-month high of $8.00. The firm’s 50-day simple moving average is $6.67 and its 200 day simple moving average is $6.17. The company has a quick ratio of 11.78, a current ratio of 11.78 and a debt-to-equity ratio of 0.10. The company has a market cap of $460.28 million, a price-to-earnings ratio of -7.42 and a beta of 1.07.

Analyst Ratings Changes

Several equities analysts recently issued reports on ALDX shares. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Aldeyra Therapeutics in a report on Friday, March 10th. Citigroup lifted their target price on shares of Aldeyra Therapeutics from $23.00 to $28.00 in a research note on Friday, March 10th.

Hedge Funds Weigh In On Aldeyra Therapeutics

Institutional investors have recently modified their holdings of the stock. ExodusPoint Capital Management LP increased its holdings in shares of Aldeyra Therapeutics by 11.7% in the second quarter. ExodusPoint Capital Management LP now owns 22,495 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 2,364 shares in the last quarter. International Assets Investment Management LLC boosted its position in Aldeyra Therapeutics by 4.8% in the 2nd quarter. International Assets Investment Management LLC now owns 59,875 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 2,750 shares during the last quarter. Dorsey Wright & Associates acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter valued at $25,000. JPMorgan Chase & Co. raised its position in shares of Aldeyra Therapeutics by 21.3% during the first quarter. JPMorgan Chase & Co. now owns 22,835 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 4,012 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Aldeyra Therapeutics by 3.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 132,908 shares of the biotechnology company’s stock valued at $591,000 after acquiring an additional 4,523 shares during the period. 63.11% of the stock is owned by institutional investors.

Aldeyra Therapeutics Company Profile

(Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.